Phase II trial of carboplatin/gemcitabine plus bevacizumab in advanced non-small cell lung cancer
Latest Information Update: 27 Feb 2017
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2005 New trial record.